US drug maker markets diabetes drug byetta in China
- Source: Caijing.com.cn
- [08:30 August 26 2009]
- Comments
US drug maker Eli Lilly and Co. said it started marketing its diabetes drug Byetta in China on August 23, signaling renewed competition in the niche market.
Eli Lilly previously sold two diabetes drugs, Humulin and Humalog, in China.
In 2008, Denmark's Novo Nordisk, French drug maker Sanofi-Aventis and Eli Lilly accounted for about 95 percent of the high-end diabetes drug market in China.
David Ricks, president and general manager of Eli Lilly China, said the company will introduce more diabetes drugs and treatment devices to China within the next five years.
